Rozanolixizumab

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Rozanolixizumab (UCB7665) 是一种人源化的高亲和力抗人新生儿 Fc 受体 (FcRn) 单克隆抗体 (IgG4P)，用于降低自身免疫和同种免疫疾病中致病性 IgG 的研究。

Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases.

Rozanolixizumab binds to human FcRn and cynomolgus monkey FcRn with a similar affinity at both pH 6.0 (Kd 23 pM and 25 pM, human and cynomolgus monkey, respectively) and pH 7.4 (34 pM and 53 pM, human and cynomolgus monkey, respectively. Rozanolixizumab is observed to inhibit the recycling (IC50 0.41 nM) of human IgG by human FcRn-transfected MDCK cells in a dose-dependent manner. Recycling of IgG was also inhibits in cynomolgus monkey FcRn-transfected MDCK cells (IC50 0.98nM). Rozanolixizumab causes an increase in intracellular IgG AF647.

Intravenous (IV) rozanolixizumab dosing in cynomolgus monkeys demonstrated non-linear pharmacokinetics indicative of target-mediated drug disposition; single IV rozanolixizumab doses (30 mg/kg) in cynomolgus monkeys reduced plasma IgG concentration by 69% by Day 7 post-administration. Daily IV administration of rozanolixizumab (initial 30 mg/kg loading dose; 5 mg/kg daily thereafter) reduced plasma IgG concentrations in all cynomolgus monkeys, with low concentrations maintained throughout the treatment period (42 days).

——

Others

Other Targets

Others

——

——

1584645-37-3

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years